Align Technology Inc Stock Price, News & Analysis

Align Technology (ALGN) has announced plans to repurchase $225 million of its common stock through open market repurchases, completing its $1.0 billion stock repurchase program approved in January 2023.

CFO John Morici stated this decision reflects the company's strong balance sheet, cash flow generation, and management's confidence in capitalizing on market opportunities while providing shareholder value. The repurchases will be executed via a Rule 10b5-1 trading plan and are expected to be completed by early May 2025, funded with Align's cash on hand.

As of December 31, 2024, Align had approximately 73.8 million shares outstanding and $1,043.9 million in cash and cash equivalents. The company continues to focus on making its Invisalign® System the standard of care in orthodontics through its doctor-centered model.

Align Technology (NASDAQ: ALGN) announced that its Invisalign Palatal Expander System has received approval from the Turkish Medicines and Medical Device Agency (TMMDA) and is now available in Turkey. The system offers a removable, safe alternative to traditional palatal expanders for skeletal and dental expansion in patients of all ages.

The system consists of customized 3D-printed devices designed using iTero intraoral scans and proprietary orthodontic software. Combined with Invisalign First™ aligners, it provides a complete early intervention treatment solution for Phase 1 treatment, which represents 20% of orthodontic case starts annually.

The expansion devices are created in small increments to gradually expand a patient's narrow maxilla (upper jaw). This innovation enhances Align's digital orthodontics portfolio, offering doctors improved efficiency and patients better treatment experiences in the EMEA region.

Align Technology (ALGN) reported Q4 2024 total revenues of $995.2 million, up 4.0% year-over-year, with full-year 2024 revenues reaching $4.0 billion, up 3.5% from 2023. Q4 Clear Aligner volumes increased 6.1% year-over-year, while Systems and Services revenues grew 14.9%.

The company's Q4 operating margin was 14.5%, with diluted EPS of $1.39 (GAAP) and $2.44 (non-GAAP). Full-year 2024 operating margin was 15.2%, with diluted EPS of $5.62 (GAAP) and $9.33 (non-GAAP). Foreign exchange impacts negatively affected 2024 revenues by approximately $38.5 million.

Notable achievements include reaching 271,600 active Invisalign trained practitioners and treating 19.5 million patients globally. The company repurchased $352.9 million of common stock in 2024 and ended the year with $1,043.9 million in cash and cash equivalents.

Align Technology (NASDAQ: ALGN) has announced that NFL quarterback Patrick Mahomes has joined the Invisalign Smile Squad as a brand ambassador. Through a multi-year agreement, Mahomes will share his personal experience with Invisalign clear aligners through a multi-channel campaign.

The Invisalign Smile Squad, launched in 2017, is part of Align's strategy to increase awareness and educate consumers about Invisalign treatment benefits. The program collaborates with regional and global influencers who share their Invisalign treatment journeys across social media platforms including TikTok, Instagram, YouTube, and Snapchat.

Mahomes, the Kansas City Chiefs quarterback, chose Invisalign aligners over traditional braces, citing his focus on optimizing performance and health as an athlete.

Align Technology (ALGN) has announced it will release its fourth quarter and 2024 financial results on Wednesday, February 5, 2025, after market close at 4:00 p.m. ET. The company will host a conference call at 4:30 p.m. ET to discuss the results, which will also be available as a live audio webcast.

The company has also revealed its tentative earnings release dates for fiscal 2025: Q1 on April 30, Q2 on July 30, and Q3 on October 29. Align Technology is a global medical device company specializing in the Invisalign® System, iTero™ intraoral scanners, and exocad™ CAD/CAM software, serving over 271,000 doctor customers and having treated approximately 18.9 million patients with the Invisalign System over 27 years.

Align Technology has received CE Mark in Europe and MHRA registration in the UK for its Invisalign® Palatal Expander System. This innovative 3D-printed device offers a removable alternative to traditional palatal expanders for treating narrow maxilla in patients with primary, mixed, or permanent dentition. Combined with Invisalign First™ aligners, it provides doctors with a complete early intervention treatment solution for both skeletal and dental arch expansion. The system is approved for broad patient applicability, including growing children, teens, and adults. The product is expected to be commercially available across EMEA in Q1 2025.

Align Technology hosted its 2024 Invisalign Ortho Summit, a premier educational event focused on digital practice transformation and treatment experiences. The three-day summit attracted over 1,000 doctors and practice team members who participated in hands-on experiences, clinical training, and practice growth strategies. The event showcased the Align Digital Platform and innovations including the Invisalign System with mandibular advancement, Invisalign Palatal Expander System, and Invisalign First. The Innovation Hub demonstrated digital tools and resources, while breakout sessions covered topics from clinical best practices to patient experience optimization.

Align Technology has launched its 2025 Annual Research Award Program, offering up to $300,000 in funding for university faculty conducting dental and orthodontic research globally. The program, which has funded approximately $3.75 million in research since 2010, will distribute twelve one-year awards of up to $25,000 each across Americas, EMEA, and APAC regions. Full-time and part-time faculty at universities where Invisalign® treatment or iTero™ scanner is available can apply until March 7, 2025, with winners announced by June 2, 2025.

Align Technology (ALGN) has announced its participation in four upcoming financial conferences in November and December 2024. The company will present at the UBS Global Healthcare Conference in Rancho Palos Verdes, the Jefferies London Healthcare Conference in England, the Piper Sandler Healthcare Conference in New York, and the Evercore HealthCONx Conference in Coral Gables. CFO John Morici will attend all events, with CEO Joseph Hogan joining for the London conference.

All presentations will be accessible via webcast through Align's Investor Relations website, with recordings available for approximately three months afterward. Align Technology is known for its Invisalign System, iTero intraoral scanners, and exocad CAD/CAM software, serving over 271,000 doctors globally.